PHARMACY

Humana adds new features to AchieveSolutions

BY Alaric DeArment

LOUISVILLE, Ky. Humana Military Healthcare Services and ValueOptions, Humana’s subcontractor for behavioral health in the southern region, have added new educational features to the AchieveSolutions behavioral health portal.

ValueOptions developed the Web-based portal, which allows beneficiaries in the southern region to seek information, educational materials and self-assessment tools on behavioral health, addiction and recovery, life events and daily living skills.

“As the global war on terror continues and the need for behavioral health resources increases for service members and families, Humana military and our valued partner ValueOptions will be here to meet those needs,” Humana Military president and chief executive officer said. “We are proud to offer the highest quality of resources available to our beneficiaries.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Glue-like bacterial sugar could lead to vaccine

BY Alaric DeArment

LONDON A study has found that when manipulated with chemicals, a sugar that drug-resistant bacteria secrete triggered an immune response in animals.

The study, presented last week at the Dublin, Ireland, meeting of the Society for General Microbiology used a glue-like sugar that bacteria produce to protect themselves from antibiotics called PNAG.

PNAG alone does not produce an immune response in most people and animals, but the researchers, from the Harvard Medical School, hope that formulations of it do.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

FDA announces likely delay on Novo Nordisk diabetes drug

BY Alaric DeArment

WASHINGTON The Food and Drug Administration has announced that it will be unable to meet the user fee deadline for a timely approval of Novo Nordisk’s drug liragludite.

The FDA will not be able to make an approvability decision until March 23 for the drug, a treatment for Type 2 diabetes. Novo Nordisk had submitted an approval application for the drug on May 23.

The standard review period for FDA action on approval applications is 10 months. Because the agency’s advisory committee meeting will take place shortly before March 23, however, its decision will probably be delayed by a further two months, the company said.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?